Skip to main content

. 1978 Dec;6(6):538–540. doi: 10.1111/j.1365-2125.1978.tb00881.x

Platelet aggregation and chlorpromazine therapy.

D J Boullin, J M Know, J R Peters, M W Orr, M G Gelder, D G Grahame-Smith

PMCID: PMC1429706 PMID: 728326

538

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Benedict C. R., Grahame-Smith D. G. Plasma noradrenaline and adrenaline concentrations and dopamine-beta-hydroxylase activity in patients with shock due to septicaemia, trauma and haemorrhage. Q J Med. 1978 Jan;47(185):1–20. [PubMed] [Google Scholar]
Boullin D. J., Glenton P. A. Characterization of receptors mediating 5-hydroxytryptamine- and catecholamine-induced platelet aggregation, assessed by the actions of alpha- and beta-blockers, butyrophenones, 5-HT antagonists and chlorpromazine. Br J Pharmacol. 1978 Apr;62(4):537–542. doi: 10.1111/j.1476-5381.1978.tb07758.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
Boullin D. J., Woods H. F., Grimes R. P., Grahame-Smith D. G. Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. Br J Clin Pharmacol. 1975 Feb;2(1):29–35. doi: 10.1111/j.1365-2125.1975.tb00468.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
Buchsbaum M. S., Coursey R. D., Murphy D. L. The biochemical high-risk paradigm: behavioral and familial correlates of low platelet monoamine oxidase activity. Science. 1976 Oct 15;194(4262):339–341. doi: 10.1126/science.968488. [DOI] [PubMed] [Google Scholar]
Orr M. W., Boullin D. J. The ralationship between changes in 5-HT induced platelet aggregation and clinical state in patients treated with fluphenazine. Br J Clin Pharmacol. 1976 Oct;3(5):925–928. doi: 10.1111/j.1365-2125.1976.tb00648.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

ACTIONS

RESOURCES